Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Oppenheimer Holdings lowered their Q3 2017 EPS estimates for Sarepta Therapeutics in a note issued to investors on Thursday. Oppenheimer Holdings analyst H. Singh now anticipates that the biotechnology company will post earnings per share of ($0.78) for the quarter, down from their prior estimate of ($0.55). Oppenheimer Holdings currently has a “Buy” rating and a $76.00 target price on the stock. Oppenheimer Holdings also issued estimates for Sarepta Therapeutics’ Q4 2017 earnings at ($0.90) EPS, FY2018 earnings at ($2.25) EPS, FY2019 earnings at ($1.67) EPS and FY2020 earnings at $0.97 EPS.

Several other equities research analysts have also issued reports on the company. SunTrust Banks, Inc. upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $30.00 to $30.97 in a report on Wednesday, April 5th. Vetr lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price target for the company. in a report on Monday, May 22nd. Cowen and Company reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. Robert W. Baird reiterated an “outperform” rating and set a $102.00 price target on shares of Sarepta Therapeutics in a report on Sunday, April 23rd. Finally, Nomura restated a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Eight analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $61.28.

TRADEMARK VIOLATION WARNING: “Q3 2017 Earnings Estimate for Sarepta Therapeutics, Inc. Issued By Oppenheimer Holdings (NASDAQ:SRPT)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/19/q3-2017-earnings-estimate-for-sarepta-therapeutics-inc-issued-by-oppenheimer-holdings-nasdaqsrpt-updated-updated-updated.html.

Sarepta Therapeutics (SRPT) opened at 43.95 on Monday. Sarepta Therapeutics has a 12-month low of $22.61 and a 12-month high of $63.73. The company has a 50-day moving average of $34.41 and a 200 day moving average of $32.31. The stock’s market cap is $2.42 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the previous year, the business posted ($1.19) EPS. The company’s quarterly revenue was up 350000.0% on a year-over-year basis.

Several hedge funds have recently added to or reduced their stakes in SRPT. Prentiss Smith & Co. Inc. boosted its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth about $127,000. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,800 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Sarepta Therapeutics during the first quarter worth about $209,000. Finally, Baird Financial Group Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth about $223,000. Institutional investors and hedge funds own 73.09% of the company’s stock.

In other news, SVP Shamim Ruff sold 12,138 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the sale, the senior vice president now directly owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sandesh Mahatme sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the sale, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.